Search

Your search keyword '"Furman, R"' showing total 502 results

Search Constraints

Start Over You searched for: Author "Furman, R" Remove constraint Author: "Furman, R"
502 results on '"Furman, R"'

Search Results

1. Comprehensive Analysis of Pain Syndrome in Patients With Mandibular Fractures Treated With Nucleo CMP Forte

2. Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study

4. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

5. P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY

6. P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

7. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

8. Astrophysics at n_TOF facility

12. Updated efficacy including subgroup analyses and safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma: 35

13. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors: 34

17. FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

20. Is ritual circumcision a risk factor for neonatal urinary tract infections?

21. Evidence for children's online integration of simultaneous information from speech and iconic gestures: An ERP study

24. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

26. Health care social work

27. 1992 Scientific Session of the Society of American Gastrointestinal Surgeons (SAGES) Washington, D.C., USA, April 11–12, 1992

30. PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

31. A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukaemia Applicable to Patients Treated with Novel Therapies and Standard of Care

45. Serum Lipoproteins

48. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

49. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

50. Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

Catalog

Books, media, physical & digital resources